News

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in ...
pharmaphorum2d
Boehringer advances oral therapy for geographic atrophy
Boehringer Ingelheim has started a proof-of-concept trial of a drug that could offer the first oral treatment for geographic ...
TipRanks on MSN1d
Cognition Therapeutics presents preclinical data on zervimesine at ARVO
Cognition Therapeutics (CGTX) reported preclinical data this week at the Association for Research in Vision and Ophthalmology showing the ...
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial ...
Ophthalmology Times4d
ARVO 2025: Dr. Jogin Desai provides Phase 2 updates from a first-in-human RPE cell suspension trial
At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, the Eye Care Network caught up with Jogin Desai. Dr. Desai is the founder of Eyestem Research, a biotechnology ...
bjo.bmj6d
The tellurium redox immunomodulating compound AS101 inhibits IL-1β-activated inflammation in the human retinal pigment epithelium
In this study, we wished to elucidate whether AS101 could mitigate pro-inflammatory activity in human retinal pigment epithelial (RPE) cells, which are heavily involved in ocular immune responses, ...
Managed Healthcare Executive2d
Ryan Flinn
Patients who were positive for cytomegalovirus had more immune cells circulating in their blood before they started immunotherapy. This may be one reason why these patients responded better to certain ...